Literature DB >> 8364905

Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.

G Richter1, S Krüger-Krasagakes, G Hein, C Hüls, E Schmitt, T Diamantstein, T Blankenstein.   

Abstract

Expression of cytokines in tumor cells provides a sensitive modality to analyze the consequences of local cytokines in vivo on tumor infiltrating cells and tumorigenicity. We have transfected Chinese hamster ovary (CHO) cells with an interleukin 10 (IL-10) expression vector. CHO-IL10 cells although unaltered with respect to their in vitro growth lost tumorigenicity, both in nude and in SCID mice and in an IL-10 dose dependent manner. In addition, CHO-IL10 cells suppressed the growth of equal numbers of coinjected but not of contralaterally injected CHO cells. Immunohistology with anti-CR3/Mac-1 and anti-Mac-3 monoclonal antibodies revealed that CHO tumors were substantially infiltrated by macrophages. However, in CHO-IL10 tumors macrophages were virtually absent within the tumor tissue. Our results suggest that IL-10 indirectly suppresses tumor growth of certain tumors by inhibiting infiltration of macrophages which may provide tumor growth promoting activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364905

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Authors:  Zhaojun Sun; Julien Fourcade; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; John M Kirkwood; Hassane M Zarour
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

Review 2.  Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

Authors:  Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 3.  Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Authors:  F Salazar-Onfray
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 4.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells.

Authors:  A B Geldhof; J Van Ginderachter; P Vandersteen; G Raes; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

6.  Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.

Authors:  H L Kaufman; J B Rao; K R Irvine; V Bronte; S A Rosenberg; N P Restifo; K R Irivine
Journal:  J Immunother       Date:  1999-11       Impact factor: 4.456

7.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

8.  Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.

Authors:  K S Chapple; E J Cartwright; G Hawcroft; A Tisbury; C Bonifer; N Scott; A C Windsor; P J Guillou; A F Markham; P L Coletta; M A Hull
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

Review 9.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

10.  Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.

Authors:  Tiva T VanCleave; Jason H Moore; Marnita L Benford; Guy N Brock; Ted Kalbfleisch; Richard N Baumgartner; James W Lillard; Rick A Kittles; La Creis R Kidd
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.